Abstract 41P
Background
Prostate cancer is the second leading cause of cancer death among men in the United States. Metastatic castration-resistant prostate cancer (mCRPC) is an advanced disease stage in which patients ultimately fail androgen-deprivation therapies and exhibit a poor survival rate. Recently, prostate-specific membrane antigen (PSMA) has been validated as a mCRPC tumor antigen with its over-expression in tumors and low expression in healthy tissues. Using an expanded genetic code to create Engineered Precision Biologics, Ambrx has developed ARX517, a PSMA-targeted antibody drug conjugate (ADC), which is composed of a humanized anti-PSMA antibody site-specifically conjugated to a tubulin inhibitor drug-linker at a drug-to-antibody ratio of 2. After binding to PSMA, ARX517 is internalized and catabolized, leading to cytotoxic payload delivery and cellular apoptosis. To minimize premature payload release and maximize delivery to tumor microenvironments, ARX517 employs a non-cleavable PEG linker and stable oxime conjugation chemistry, enhancing systemic stability.
Methods
ARX517 was evaluated in multiple pre-clinical pharmacology and toxicology models using standard methodology.
Results
In vitro studies demonstrate that ARX517 selectively induces cytotoxicity of PSMA-expressing tumor lines. ARX517 exhibited a long terminal half-life and high serum exposure in mice, and dose-dependent anti-tumor activity in both enzalutamide-sensitive and -resistant CDX and PDX prostate cancer models. Repeat dose toxicokinetic studies in non-human primates demonstrated ARX517 was tolerated at exposures well above therapeutic exposures in mouse pharmacology studies, indicating a wide therapeutic index.
Conclusions
In summary, ARX517 inhibited tumor growth in diverse mCRPC models, demonstrated a tolerable safety profile in monkeys, and had a wide therapeutic index based on preclinical exposure data. Based on strong preclinical data and recent clinical validation of PSMA targeting, ARX517 is being evaluated in a phase 1/2 clinical trial (NCT04662580).
Clinical trial identification
Editorial acknowledgement
Mark English, PhD, of Cancer Communications and Consultancy Ltd, Cheshire, UK, provided editorial assistance (funded by Ambrx).
Legal entity responsible for the study
Ambrx.
Funding
Ambrx.
Disclosure
S. Zhang, D. Mills, J.Y. Kim, N. Knudsen, J. Nelson, Y. Buechler, L. Skidmore: Financial Interests, Personal, Full or part-time Employment: Ambrx.
Resources from the same session
24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Presenter: Anastasia Frolova
Session: Poster session 09
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09